N-(2-(1H-indol-3-yl)ethyl)-3-nitrobenzenesulfonamide | 32539-40-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-(1H-indol-3-yl)ethyl)-3-nitrobenzenesulfonamide
• 英文别名: N-[2-(1H-indol-3-yl)ethyl]-3-nitrobenzenesulfonamide
• CAS: 32539-40-5
• 化学式: C₁₆H₁₅N₃O₄S
• 分子量: 345.379
• InChiKey: KFEVJYWHPWLCFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(2-(1H-indol-3-yl)ethyl)-3-nitrobenzenesulfonamide 在 N-甲基吗啉 、 tin(ll) chloride 、 氯甲酸异丁酯 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.08h， 生成 Hexadecanoic acid (2-{3-[2-(1H-indol-3-yl)-ethylsulfamoyl]-phenylcarbamoyl}-ethyl)-amide
  参考文献：
  名称：

  Design, synthesis and early structure–activity relationship of farnesyltransferase inhibitors which mimic both the peptidic and the prenylic substrate

  摘要：

  Inhibition of the farnesylation of ras proteins has been identified as a promising target in tumor therapy. Only a few farnesyltransferase inhibitors are bisubstrate analogues displaying features of both substrates, the farnesylpyrophosphate and the C-terminal CAAX-tetrapeptide sequence of the res protein. These known bisubstrate analogues consist of an AAX-tripeptide and a farnesyl residue connected through various linkers. We have developed a class of novel compounds that mimic a bisubstrate inhibitor structure and that differ from the known ones by lacking peptidic or farnesylic substructures. Long chain fatty acids and aryl-substituted carboxylic acids were used as farnesyl surrogates. These structures were linked to isoleucine amide, benzoic acid amide, N-substituted aminobenzenesulfonamides and N-alpha-aryl-substituted methionine derivatives, respectively, which function as AA- or AAX-mimetics. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00138-3
• 作为产物：
  描述：

  色胺 、 3-硝基苯磺酰氯 在 sodium carbonate 作用下， 以 二氯甲烷 为溶剂， 生成 N-(2-(1H-indol-3-yl)ethyl)-3-nitrobenzenesulfonamide
  参考文献：
  名称：

  磺酰胺基吲哚作为芳香化酶抑制剂的合成，分子对接和QSAR研究

  摘要：

  三十四吲哚轴承磺胺类药物（11 - 44）的合成并评价它们的抗芳香酶的活动。有趣的是，所有吲哚衍生物均抑制了芳香化酶，IC 50范围为0.7–15.3μM。吲哚（27–36）比酮康唑具有更高的芳香化酶抑制活性。具有甲氧基的苯氧基类似物28和34显示为最有效的化合物，具有亚微摩尔IC 50值（分别为0.7和0.8μM），而不会影响正常细胞系。分子对接表明，吲哚28，30和34它可能在芳香酶口袋上占据相同的结合位点，并与天然底物（雄烯二酮）共有多个结合残基，这表明竞争性结合可能是该化合物的抑制方式。最有效的类似物28可以模拟天然雄烯二酮与芳香化酶上MET374和ASP309残基的氢键相互作用。QSAR模型还表明，与邻苯氧基化合物相比，对苯氧基吲哚（28）具有更高的电负性描述符MATS6e值和更高的抑制活性（34）。）。这项研究强调了一系列有前途的吲哚，有可能被开发为新型的芳香酶抑制剂。

  DOI：

  10.1016/j.ejmech.2017.10.057

文献信息

• Small-Molecule Inhibitors That Target Protein-Protein Interactions in the RAD51 Family of Recombinases
  作者：Duncan E. Scott、Anthony G. Coyne、Ashok Venkitaraman、Tom L. Blundell、Chris Abell、Marko Hyvönen

  DOI：10.1002/cmdc.201402428

  日期：2015.2

  The development of small molecules that inhibit protein–protein interactions continues to be a challenge in chemical biology and drug discovery. Herein we report the development of indole‐based fragments that bind in a shallow surface pocket of a humanised surrogate of RAD51. RAD51 is an ATP‐dependent recombinase that plays a key role in the repair of double‐strand DNA breaks. It both self‐associates

  抑制蛋白质与蛋白质相互作用的小分子的发展仍然是化学生物学和药物发现中的挑战。在这里，我们报道了结合吲哚基片段的发展，该片段结合在RAD51人性化替代物的浅表囊中。RAD51是一种依赖于ATP的重组酶，在双链DNA断裂的修复中起关键作用。它既可以自缔合，与DNA形成细丝结构，又可以通过常见的“ FxxA”四肽基序与BRCA2蛋白相互作用。我们精心设计了先前确定的靶向FxxA序列位点的片段，并开发了比初始片段强约500倍的小分子抑制剂。铅化合物与BRCA2衍生的Ac-FHTA-NH 2竞争肽和RAD51的自缔合肽，但它们对ATP结合没有影响。这项研究是首次报道针对这一具有挑战性的目标的小分子量片段的研究。
• Synthesis, biological evaluation, and docking study of indole aryl sulfonamides as aromatase inhibitors
  作者：Marialuigia Fantacuzzi、Barbara De Filippis、Marialucia Gallorini、Alessandra Ammazzalorso、Letizia Giampietro、Cristina Maccallini、Zeineb Aturki、Enrica Donati、Reham S. Ibrahim、Eman Shawky、Amelia Cataldi、Rosa Amoroso

  DOI：10.1016/j.ejmech.2019.111815

  日期：2020.1

  In order to identify new aromatase enzyme inhibitors, thirty aryl sulfonamide derivatives containing an indole nucleus have been synthesized. The enzyme inhibition assay showed that four compounds inhibit aromatase in the sub-micromolar range. Loading concentrations of these four compounds were afterwards tested for cell viability and cytotoxicity on MCF7 human breast cancer cells, revealing a time-

  为了鉴定新的芳香酶抑制剂，已经合成了三十种含有吲哚核的芳基磺酰胺衍生物。酶抑制试验表明，有四种化合物在亚微摩尔范围内抑制了芳香化酶。随后测试了这四种化合物的负载浓度对MCF7人乳腺癌细胞的细胞生存力和细胞毒性，发现从培养开始（0-72小时），活性代谢细胞随时间和剂量的减少而减少。浓度为100μM。同样，在暴露的早期（24小时），释放的LDH最多可提高40％。最后，对接研究表明，最好的活性化合物有效地结合在芳香酶的活性位点上。QSAR模型证明了高的HBD值和低的HBA水平是主要要求。
• Inhibitors of 15-lipoxygenase
  申请人：Murugesan Natesan

  公开号：US20060063823A1

  公开（公告）日：2006-03-23

  The present invention provides inhibitors of 15-LO according to Formula I, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.

  本发明提供了15-LO的抑制剂，其符合公式I，以及包含这些抑制剂的药物组合物，并且使用这些化合物和组合物治疗与15-LO级联相关的疾病的方法。
• US7754755B2
  申请人：——

  公开号：US7754755B2

  公开（公告）日：2010-07-13
• Design, synthesis and early structure–activity relationship of farnesyltransferase inhibitors which mimic both the peptidic and the prenylic substrate
  作者：Martin Schlitzer、Markus Böhm、Isabel Sattler、Hans-Martin Dahse

  DOI：10.1016/s0968-0896(00)00138-3

  日期：2000.8

  Inhibition of the farnesylation of ras proteins has been identified as a promising target in tumor therapy. Only a few farnesyltransferase inhibitors are bisubstrate analogues displaying features of both substrates, the farnesylpyrophosphate and the C-terminal CAAX-tetrapeptide sequence of the res protein. These known bisubstrate analogues consist of an AAX-tripeptide and a farnesyl residue connected through various linkers. We have developed a class of novel compounds that mimic a bisubstrate inhibitor structure and that differ from the known ones by lacking peptidic or farnesylic substructures. Long chain fatty acids and aryl-substituted carboxylic acids were used as farnesyl surrogates. These structures were linked to isoleucine amide, benzoic acid amide, N-substituted aminobenzenesulfonamides and N-alpha-aryl-substituted methionine derivatives, respectively, which function as AA- or AAX-mimetics. (C) 2000 Elsevier Science Ltd. All rights reserved.